Pembrolizumab and Sacituzumab govitecan
About
Membership operator: AND
Therapies: 2
Therapies
Pembrolizumab (tx:ncit:C106432)
Sacituzumab govitecan (tx:ncit:C102783)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| FDA (2) | ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative | Invasive Breast Carcinoma | Pembrolizumab, Sacituzumab govitecan |